Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Venturi

Plastic and Reconstructive Surgery Mc Lean, VA Medical Doctor

NPI 1093734717 CMS profile 139815

7601 Lewinsville Rd, Suite 400, Mc Lean, VA 22102

Open in the dashboard

General payments

$355,852

260 records reported · program years 2019–2025

Research payments

$1,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Venturi of Mc Lean, VA is reported in the CMS Open Payments database as having received $355,852 across 260 general payments and $1,500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,334 44
2024 General $29,514 34
2023 General $55,840 36
2022 General $22,157 28
2021 General $66,577 34
2020 General $32,475 26
2020 Research $1,500 1
2019 General $103,957 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Venturi
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Mark Venturi were reported at $45,334. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Mark Venturi Plastic and Reconstructive Surgery median Middle half National median
2019 $103,957 $335 $121–$1,264 $163
2020 $32,475 $162 $57–$417 $114
2021 $66,577 $245 $89–$735 $132
2022 $22,157 $325 $120–$932 $149
2023 $55,840 $343 $129–$999 $160
2024 $29,514 $390 $141–$1,085 $164
2025 $45,334 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $301,484 121 payments
  2. Medical Device Business Services, Inc. $15,750 3 payments
  3. Mentor Worldwide LLC $12,952 23 payments
  4. Davol Inc. $10,554 18 payments
  5. Allergan Inc. $10,403 30 payments
  6. Merz North America, Inc. $835 6 payments
  7. Smith+Nephew, Inc. $624 6 payments
  8. Integra LifeSciences Corporation $401 4 payments
  9. Medtronic, Inc. $350 4 payments
  10. Sientra, Inc. $334 6 payments
  11. Other $2,165 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $293,227 50 payments
  2. Travel and Lodging $37,648 51 payments
  3. Food and Beverage $11,241 152 payments
  4. Gift $9,362 5 payments
  5. Honoraria $4,375 2 payments
Products named General payments · program years 2019–2025
  1. SPY-PHI SYSTEM $127,737 35 payments
  2. DERMACELL $100,743 19 payments
  3. SPY TECHNOLOGY $97,184 33 payments
  4. 1688 $45,354 10 payments
  5. 1588 HD 3 CHIP CAMERA $22,736 4 payments
  6. MOLLI Endoscopy $13,250 1 payment
  7. MOLLI Endoscopy $13,250 1 payment
  8. MOLLI Endoscopy $13,250 1 payment
  9. MOLLI Endoscopy $13,250 1 payment
  10. 1688 HD 3 CHIP CAMERA $12,500 1 payment
  11. Other $62,007 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $1,500 1 payment

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$49,769

Medicare's payments for the services billed

Medicare patients

53

Average age 71

Services billed

195

53 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 47%
Arthritis 43%
Osteoporosis 34%
Heart failure 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $141
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record